| Document |
Document Title |
|
WO/2024/006537A9 |
The disclosure relates to methods of using bile acid derivatives for the treatment and/or prevention of cognitive disorders, diseases, or conditions.
|
|
WO/2023/245086A1 |
Compositions, methods, and kits of small molecular weight agents can bind and stimulate the Fc-γ-activating receptors to enhance humoral immune-response and immune-effector cell response by improving immune-effector cell and/or antibody...
|
|
WO/2023/192221A1 |
The present disclosure provides solid forms of sodium chenodeoxycholate (NaCDC), as well as compositions thereof and methods of using and preparing the same.
|
|
WO/2023/149727A1 |
Betulin is a natural pentacyclic triterpene, and is contained in birch tree, especially its outer bark. Betulin can be used as a hydrophobic building block for production of biobased surfactants. This invention is related to amphiphilic ...
|
|
WO/2023/028278A2 |
Compounds are provided according to Formulae (A-I), (B-I), (C-I), (D-I), (E-I), (F-I), (G-I), and (H-I) : and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present disclosure are con...
|
|
WO/2022/215048A1 |
The present invention refers to a process for the industrial-scale preparation of 17β-hydroxy- 6β,7β;15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21-carb
oxylic acid y-lactone, known by the common name of Drospirenone, in the form of ...
|
|
WO/2022/170364A1 |
Disclosed herein are a modified guayule resin product and related processes for preparing the modified guayule resin product. The modified guayule resin product comprises a mixture of argentatins having at least one functional group, whe...
|
|
WO/2022/133477A1 |
Disclosed herein are a modified guayule resin product and related processes for preparing the modified guayule resin product. The modified guayule resin product comprises a mixture of argentatins having at least one functional group, whe...
|
|
WO/2022/115381A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein ring D and the substituents are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a p...
|
|
WO/2022/100722A1 |
A 5,6-epoxy sterol compound intermediate, and a preparation method therefor and an application thereof. The intermediate has a chemical structure represented by formula I, wherein R is selected from -CH 2OCOR 1 or -CH＝CH-CO(O)R 1, and ...
|
|
WO/2022/045354A1 |
The present invention addresses the problem of providing the development of a simpler, more efficient method for producing a phytosterol starting material. The present invention is a method for producing a phytosterol starting material, ...
|
|
WO/2022/021107A1 |
A γ-oryzanol preparation method, including the following steps: (a) using a supercritical fluid and extracting an extract fluid containing γ-oryzanol from a raw material containing γ-oryzanol; (b) using a solid-liquid separation means...
|
|
WO/2021/217275A1 |
The present application discloses application of extracts and formulations thereof of Boswellia resin as well as purified or partly purified boswellic acids as antiviral and immunomodulatory agents against viruses that cause upper or low...
|
|
WO/2021/098680A1 |
A method for preparing oryzanol by using soapstock containing oryzanol as a raw material, comprising the following steps: 1) alkali alcohol hot dissolving; 2) thermal insulation and fine filtration; 3) thermal insulation and ultrafiltrat...
|
|
WO/2021/002821A1 |
The invention, is related to Astragaloside VII, which isisolated from Astragalus, and synthesis of its analogs thereof that can be used in veterinary, prophylactic and therapeutic human vaccines and, the examination of the immunomodulato...
|
|
WO/2020/264495A1 |
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...
|
|
WO/2020/185610A1 |
The present disclosure is concerned with taccalonolide analogs and conjugated taccalonolide analogs useful as cellular probes and in the treatment of, for example, hyperproliferative disorders such as cardiovascular diseases and cancer. ...
|
|
WO/2020/006510A1 |
The present invention concerns novel pharmaceutically active triterpene amine derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicament...
|
|
WO/2019/021122A2 |
The present invention relates to novel Liver X Receptor (LXR) modulators, their use in diagnostic and therapy, more particularly in the treatment of diseases associated with LXR, such as cancer, inflammation, metabolic and autoimmune dis...
|
|
WO/2018/145578A1 |
Disclosed is a method for synthesizing astragaloside IV, comprising the following steps: protecting hydroxyl groups at the 3-position and 6-position of cycloastragenol using protecting groups R1; after protecting hydroxyl groups at the 1...
|
|
WO/2018/029604A1 |
The present invention relates to C-3 novel triterpenone with C-17 reverse amide compounds of Formula (I); and pharmaceutically acceptable salts thereof, wherein ring Formula (II), R1, R2, R3, R4, R5, R6, R7, 'n' and 'm' are as defined in...
|
|
WO/2018/029610A1 |
The present invention relates to C-3 novel triterpenone with C-17 N-amide compounds of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and 'X' are as defined in formula (I). The invention also r...
|
|
WO/2018/029602A1 |
The present invention relates to C-3 novel triterpenone with C-28 heterocycle compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, W, ring X and ring Y are as defined in formula (I). The present invention ...
|
|
WO/2018/025247A1 |
The present invention relates to C-3 novel triterpenone with C-28 diamide compounds of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and 'm' are as defined in formula (I). The present inventio...
|
|
WO/2017/215677A2 |
Disclosed are a carbocisteine pharmaceutical composition and effects thereof for treating leukemia. The carbocisteine pharmaceutical composition provided in the present invention comprises carbocisteine and a naturally produced compound ...
|
|
WO/2017/021852A1 |
Method for the separation of at least one isoprenic constituent from the resin of a plant of guayule and/or of the guayule type comprising the steps of: a) providing a defatted resin of guayule and/or of the guayule type; b) subjecting t...
|
|
WO/2016/173524A1 |
Disclosed in the present application are the compounds as shown in formulae I, II, III, IV or V, tautomers thereof, stereoisomers thereof or pharmaceutically acceptable salts thereof, and also disclosed is the use thereof in preparing dr...
|
|
WO/2016/007535A1 |
This disclosure concerns compounds which are useful as HSP90/CDC37 antagonists and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the interaction of HSP90 and CDC37. This disclosur...
|
|
WO/2014/167386A1 |
A process is disclosed wherein, using either 17a-(3-hydroxypropyl)-6p,7p;15p,16p- dimethylene-5p-androstane-3p,5,17p-triol (II) or 3β,5^ΐΙ^κ^-6β,7β;15β,16β- dimethylene-5β,17α-pregnane-21,17-carbolactone (III) as starting mater...
|
|
WO/2014/128525A1 |
A process is described wherein, by employing 17a-(3-hydroxypropyl) -63,7β3;15β,16β-dimethylene-5β-androstane-3β,5,17β-tri
ol (II) as starting product, in a single stage reaction there is obtained drospirenone, (I), whereby the reac...
|
|
WO/2014/022772A1 |
In one aspect, the invention relates to methods for promoting muscle hypertrophy or decreasing adiposity by providing to an animal in need thereof an effective amount of a compound. This abstract is intended as a scanning tool for purpos...
|
|
WO/2014/011085A1 |
The invention relates to the field of medicine. Described is an effective, low-toxicity agent in the form of the methyl 2-cyano-3,12-dioxo-18βН-olean-1(2),11(9)-dien-30-oate of formula (1): which exhibits antioxidant, anti-inflammatory...
|
|
WO/2013/100811A1 |
The invention relates to the chemistry of natural and physiologically active substances and especially, to a process for obtaining an intermediate product in the synthesis of steroid hormones of the pregnane series. The process for obtai...
|
|
WO/2013/091144A1 |
The present invention relates to a compound characterized by the following Formula I or a pharmaceutically acceptable salt thereof, wherein X, Y, and Z are as described herein. Compounds of the present invention are useful for the treatm...
|
|
WO/2013/089594A1 |
The invention relates to the chemistry of natural and physiologically active substances and more particularly to a process for obtaining an intermediate product in the synthesis of steroid hormones of the pregnane series. The targeted...
|
|
WO/2013/089595A1 |
The invention relates to the chemistry of natural and physiologically active substances and more particularly to a process for obtaining an intermediate product in the synthesis of steroid hormones of the pregnane series. The targeted ta...
|
|
WO/2013/038316A1 |
The present invention relates to a method for preparation of betulinic acid from betulin. The method comprises oxidizing betulin to betulinic acid with a catalyst of formula (5), e.g. 2,2,6,6-tetramethylpiperidine 1 - oxyl (TEMPO), in th...
|
|
WO/2013/038314A1 |
The invention relates a method for preparation of betulonic acid or betulinic acid from betulin wherein the method comprises a stage for oxidizing betulin to betulonic aldehyde and/or betulinic aldehyde with Pd(ll)-catalyst catalyzed oxi...
|
|
WO/2013/038312A1 |
The present invention relates to a method for preparation of betulinic acid from betulin. The method comprises oxidizing betulin to betulinic and/or betulonic aldehyde with a ruthenium based catalyst catalyzed oxidation process in the pr...
|
|
WO/2013/020245A1 |
Disclosed are a compound characterized by the following formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof, wherein R3, L, and ...
|
|
WO/2012/160250A2 |
The present invention provides an improved method for obtaining a bark extract by hydrolysis and acidification in the presence of water. The method comprises the steps of subjecting birch bark to hydrolysis; separating the undissolved ba...
|
|
WO/2012/109752A1 |
The present invention includes novel compounds based on the tomatidine skeleton as well as composition comprising these compounds alone and in combination with known compounds, which exhibit antimicrobial activity against extracellular o...
|
|
WO/2012/107513A1 |
The invention relates to processes for obtaining 6β,7β; 15β, 16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, commonly known as Drospirenone, as well as to intermediate compounds of formula (II) useful in said process.
|
|
WO/2012/023599A1 |
A process for producing a triterpene alcohol by carrying out the following steps (A)-(C) in this order: (A) hydrolyzing γ-oryzanol with an alkali; (B) mixing the resulting alkali hydrolysate with a low-polar organic solvent to extract t...
|
|
WO/2012/016860A1 |
The invention relates to a process for the preparation of Drospirenone in high yields and purity starting from a compound of formula (2) wherein R is a hydroxyl protective group as defined in the claims, through a sequence of oxidation, ...
|
|
WO/2011/113196A1 |
Preparation method of drospirenone is disclosed, which uses 3β,5-dihydroxy-6β,7β,15β,16β-dimethylene-5β-androster-
17, 20-epoxy as the starting material and comprises the following steps: oxidizing the hydroxyl group at position 3,...
|
|
WO/2011/060634A1 |
23-hydroxy-betulinic acid derivatives, including 3-oxo-23-hydroxy-betulinic acid, 3-oxo-23-hydroxy-dihydrobetulinic acid and 23-hydroxy-dihydrobetulinic acid, their preparation methods and medical uses as antitumor and anti-HIV agents ar...
|
|
WO/2010/146042A1 |
The invention relates to processes for obtaining steroids with a spirolactone group in position 17, particularly to industrially obtaining 6β,7β; 15β,16β-dimethylene-3-oxo-17α- pregn-4-ene-21,17-carbolactone, commonly known as Drosp...
|
|
WO/2010/142705A1 |
The present invention relates to substituted steroid compounds having the formula (I) Wherein R1 is H or halogen; R2 is H, (1C-4C)alkyl, (1C-4C)acyl, glucuronyl or sulfamoyl; R3 is H or halogen; R4 is H, (1C-4C)alkyl, (2C-4C)alkenyl or (...
|
|
WO/2010/133687A1 |
The present invention relates to a compound with the following formula (I), or to a pharmaceutically acceptable salt thereof, as well as to pharmaceutical compositions including same and to the use thereof as a drug, in particular for tr...
|
